Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Total Current Liabilities (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed Total Current Liabilities for 4 consecutive years, with $26.6 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 1.24% to $26.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $26.6 million through Dec 2025, up 1.24% year-over-year, with the annual reading at $26.6 million for FY2025, 1.24% up from the prior year.
  • Total Current Liabilities hit $26.6 million in Q4 2025 for Taysha Gene Therapies, down from $28.6 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $180.5 million in Q3 2023 to a low of $22.6 million in Q1 2025.
  • Historically, Total Current Liabilities has averaged $46.3 million across 4 years, with a median of $35.5 million in 2023.
  • Biggest five-year swings in Total Current Liabilities: skyrocketed 444.53% in 2023 and later tumbled 83.74% in 2024.
  • Year by year, Total Current Liabilities stood at $62.8 million in 2022, then tumbled by 41.46% to $36.8 million in 2023, then fell by 28.65% to $26.2 million in 2024, then increased by 1.24% to $26.6 million in 2025.
  • Business Quant data shows Total Current Liabilities for TSHA at $26.6 million in Q4 2025, $28.6 million in Q3 2025, and $25.3 million in Q2 2025.